ALEC

Alector, Inc. (ALEC) is a clinical-stage biopharmaceutical company focused on advancing innovative therapies to address neurodegenerative diseases, including Alzheimer's and frontotemporal dementia. Leveraging its proprietary immuno-neurology platform, Alector aims to harness the immune system to restore neuronal health and functionality. Headquartered in South San Francisco, California, the company is committed to transforming the landscape of neurodegenerative disease treatment through its groundbreaking research and development initiatives. With a robust pipeline of product candidates, Alector is well-positioned to make significant contributions to the field of neurology.